M-145

Milnacipran hydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant^®

• 经验公式（希尔记法）: C₁₅H₂₃ClN₂O
• CAS号: 101152-94-7
• 分子量: 282.81
• EC號碼: 200-659-6
• MDL號碼: MFCD27978092
• 分類程式碼代碼: 41116107
• PubChem物質ID: 329817879
• NACRES: NA.24

属性

• 等級: certified reference material
• 品質等級: 300
• 形狀: liquid
• 特點: Snap-N-Spike^®/Snap-N-Shoot^®
• 包裝: ampule of 1 mL
• 製造商／商標名: Cerilliant^®
• 濃度: 1.0 mg/mL in methanol (as free base)
• 技術: gas chromatography (GC): suitable; liquid chromatography (LC): suitable
• 應用: clinical testing
• 形式: single component solution
• 儲存溫度: −20°C
• SMILES 字串: CCN(CC)C([C@]1(C2=CC=CC=C2)C[C@@H]1CN)=O.Cl
• InChI: 1S/C15H22N2O.ClH/c1-3-17(4-2)14(18)15(10-13(15)11-16)12-8-6-5-7-9-12;/h5-9,13H,3-4,10-11,16H2,1-2H3;1H/t13-,15+;/m1./s1
• InChI 密鑰: XNCDYJFPRPDERF-PBCQUBLHSA-N

说明

一般說明

Milnacipran, sold under the brand names Savella^®, Ixel^®, Dalcipran^®, or Toledomin, is a serotonin-norepinephrine reuptake inhibitor (SNRI) used in the treatment of depression. In 2009, the US Food and Drug Administration (FDA) approved milnacipran for management of the chronic pain disorder fibromyalgia, making it only the third drug approved in the US for this indication besides duloxetine and pregabalin.

應用

• Anesthetic and Analgesic Applications of Milnacipran: Review on new serotonin-norepinephrine reuptake inhibitors, highlighting Milnacipran hydrochloride′s role in anesthetic and analgesic applications, discussing its impact on pain management strategies (Fanelli et al., 2021).


• Sustained Release Delivery System for Milnacipran: Development of a novel chitosan-polycaprolactone based mucoadhesive gastro-retentive drug delivery system for Milnacipran HCl, aimed at improving bioavailability and enhancing patient compliance (Hussain et al., 2020).


• Comparative Review of Levomilnacipran and Milnacipran: Analysis of Levomilnacipran′s effectiveness compared to Milnacipran in treating major depressive disorder, focusing on efficacy, tolerability, and patient outcomes (Gautam et al., 2019).


• Antidepressant Efficacy and Side Effects: Network meta-analysis of 21 antidepressants, including Milnacipran, assessing their side effect profiles and comparative tolerability in the acute treatment of major depression (Tomlinson et al., 2019).

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Dalcipran is a registered trademark of Pierre Fabre Medicament

Ixel is a registered trademark of Pierre Fabre Medicament

Savella is a registered trademark of Forest Laboratories, Inc.

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

安全信息

• 象形圖: GHS02,GHS06,GHS08
• 訊號詞: Danger
• 危險聲明: H225,H301 + H311 + H331,H370
• 防範說明: P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311
• 危險分類: Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
• 標靶器官: Eyes
• 儲存類別代碼: 3 - Flammable liquids
• 水污染物質分類（WGK）: WGK 1
• 閃點（°F）: 49.5 °F - closed cup
• 閃點（°C）: 9.7 °C - closed cup